Post Profile

Tesaro ovarian cancer drug shows broad benefits in study

COPENHAGEN (Reuters) - Tesaro's experimental drug niraparib improved outcomes for a broad range of women with recurrent ovarian cancer in a clinical study, boosting prospects for the product, which belongs to a closely watched class of new medicines.
read more


Related Posts

Clinical Trial Analysis Suggests Drug Combination May Be Highly Effective in Recurrent Ovarian Cancer

Health : Newswise Medical News

Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Tesaro Shares Surge 82% Because Drug Slows Ovarian Cancer

Business & Finance : Forbes: Business

Shares in Tesaro, a small drug maker, soared 82% in pre-market trading after the company said its experimental medicine, niraparib, slowed the growth of ovarian tumors in a 500-patient clinical trial. Tesaro says that it plans to fi...

Ovarian cancer: combination therapy using decitabine 'effective'

Health : Medical News Today

Women with recurrent ovarian cancer showed clinical benefit when treated with a drug called decitabine before undergoing chemotherapy and a cancer vaccine. This is according to a new study published in the journal Cancer Immunology ...

Novartis challenges Pfizer with strong breast cancer drug data

Health : Reuters: Health

COPENHAGEN (Reuters) - An experimental Novartis pill given with an older drug kept advanced breast cancer in check far longer than standard treatment alone, putting it on track to challenge Pfizer's blockbuster Ibrance, data showed ...

Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

Health : EurekAlert: Health

(European Society for Medical Oncology) The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first ti...


Copyright © 2016 Regator, LLC